Philip Astley-Sparke
Founder at REPLIMUNE GROUP, INC.
Net worth: 11 M $ as of 2024-03-30
Profile
Philip Astley-Sparke is the founder and the Executive Chairman of Replimune Group, Inc., which was founded in 2015.
He is currently the Director at Replimune Ltd.
since 2015 and a Venture Partner at Forbion Capital Partners Management Holding BV since 2012.
Mr. Astley-Sparke's former positions include being the President & Chief Executive Officer of BioVex, Inc. from 2000 to 2011, President & Chief Executive Officer of BioVex Group, Inc., Chairman of uniQure NV from 2013 to 2021, Chairman of Oxyrane, Ltd.
from 2012 to 2020, an Independent Non-Executive Director at Forbion European Acquisition Corp., and Vice President & General Manager at Amgen, Inc. He also served as the President of uniQure, Inc. from 2013 to 2015.
Mr. Astley-Sparke obtained his undergraduate degree from the University of Bristol.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
REPLIMUNE GROUP, INC.
2.10% | 2023-06-29 | 1,287,970 ( 2.10% ) | 11 M $ | 2024-03-30 |
Philip Astley-Sparke active positions
| Companies | Position | Start |
|---|---|---|
| REPLIMUNE GROUP, INC. | Founder | 2015-02-28 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 2012-04-30 |
Replimune Ltd.
 Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The private company is based in Abingdon, UK and was founded in 2015. | Director/Board Member | 2015-03-17 |
Former positions of Philip Astley-Sparke
| Companies | Position | End |
|---|---|---|
| UNIQURE N.V. | Chairman | 2021-06-14 |
| Oxyrane, Ltd. | Chairman | 2019-12-31 |
uniQure, Inc.
 uniQure, Inc. BiotechnologyHealth Technology Part of uniQure NV, uniQure, Inc. provides research and development services of human gene based therapies. The private company is based in Lexington, MA. | President | 2015-01-31 |
| AMGEN INC. | Corporate Officer/Principal | 2011-11-30 |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Chief Executive Officer | 2011-03-30 |
Training of Philip Astley-Sparke
| University of Bristol | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| UNIQURE N.V. | Health Technology |
| REPLIMUNE GROUP, INC. | Health Technology |
| Private companies | 7 |
|---|---|
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
| Oxyrane, Ltd. | |
Replimune Ltd.
Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The private company is based in Abingdon, UK and was founded in 2015. | Commercial Services |
Forbion European Acquisition Corp.
 Forbion European Acquisition Corp. Financial ConglomeratesFinance Forbion European Acquisition Corp. is a blank check company. It engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded by Hugo Alexander Slootweg in 2006 and is headquartered in Wilmington, DE. | Finance |
uniQure, Inc.
uniQure, Inc. BiotechnologyHealth Technology Part of uniQure NV, uniQure, Inc. provides research and development services of human gene based therapies. The private company is based in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Philip Astley-Sparke
